Advertisement
Australia markets close in 5 hours 25 minutes

  • ALL ORDS

    8,487.10
    -11.60 (-0.14%)
     

  • ASX 200

    8,210.80
    -12.20 (-0.15%)
     

  • AUD/USD

    0.6741
    -0.0002 (-0.04%)
     

  • OIL

    75.68
    -0.17 (-0.22%)
     

  • GOLD

    2,650.50
    +11.20 (+0.42%)
     

  • Bitcoin AUD

    89,314.69
    -675.30 (-0.75%)
     

  • XRP AUD

    0.79
    +0.01 (+0.93%)
     

  • AUD/EUR

    0.6162
    +0.0003 (+0.04%)
     

  • AUD/NZD

    1.1058
    +0.0004 (+0.04%)
     

  • NZX 50

    12,765.42
    +10.84 (+0.09%)
     

  • NASDAQ

    20,241.76
    -27.10 (-0.13%)
     

  • FTSE

    8,237.73
    -6.01 (-0.07%)
     

  • Dow Jones

    42,454.12
    -57.88 (-0.14%)
     

  • DAX

    19,210.90
    -44.03 (-0.23%)
     

  • Hang Seng

    21,251.98
    +614.74 (+2.98%)
     

  • NIKKEI 225

    39,380.89
    +102.93 (+0.26%)
     

Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference

Esperion Therapeutics, Inc.
·1-min read
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc.

ANN ARBOR, Mich., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 10:55 a.m. ET.

The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.

Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on X at twitter.com/EsperionInc.

Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438